Alamar Biosciences (NASDAQ:ALMR) Upgraded to “Hold” at Zacks Research

Alamar Biosciences (NASDAQ:ALMR) was upgraded by investment analysts at Zacks Research to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

ALMR has been the subject of several other reports. Bank of America initiated coverage on shares of Alamar Biosciences in a research note on Tuesday. They set a “neutral” rating and a $27.00 price objective for the company. TD Cowen began coverage on shares of Alamar Biosciences in a research note on Tuesday. They set a “buy” rating and a $30.00 price objective for the company. Wall Street Zen upgraded Alamar Biosciences to a “hold” rating in a report on Saturday, April 25th. JPMorgan Chase & Co. began coverage on Alamar Biosciences in a report on Tuesday. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Stifel Nicolaus began coverage on Alamar Biosciences in a report on Tuesday. They set a “buy” rating and a $28.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Alamar Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.00.

Alamar Biosciences Stock Down 2.2%

Shares of Alamar Biosciences stock opened at $22.51 on Wednesday. Alamar Biosciences has a one year low of $21.50 and a one year high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last posted its quarterly earnings data on Friday, May 8th. The company reported ($1.74) EPS for the quarter. The business had revenue of $26.04 million for the quarter.

Insider Buying and Selling at Alamar Biosciences

In other news, Director Nicholas Naclerio bought 235,294 shares of the stock in a transaction on Monday, April 20th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $3,999,998.00. Following the acquisition, the director owned 507,076 shares of the company’s stock, valued at $8,620,292. This represents a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Innovation Fund Gp Illumina II bought 235,294 shares of the stock in a transaction on Monday, April 20th. The stock was purchased at an average price of $17.00 per share, with a total value of $3,999,998.00. Following the completion of the acquisition, the insider directly owned 507,076 shares in the company, valued at approximately $8,620,292. This trade represents a 86.57% increase in their position. The disclosure for this purchase is available in the SEC filing.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.